Characteristics and clinical courses of patients with atypical haemolytic uraemic syndrome on dialysis withdrawal after eculizumab treatment: sub-analysis of post-marketing surveillance in Japan.

ABSTRACT:

Background

Atypical haemolytic uraemic syndrome (aHUS) leads to acute kidney injury, necessitating dialysis in about half of patients. A certain proportion of patients treated with C5 inhibitors discontinue dialysis; however, little is known about the patient characteristics and clinical courses relating to discontinuation.

Methods

We compared the characteristics and clinical courses of patients with aHUS on dialysis at the initiation of eculizumab during post-marketing surveillance in Japan, stratified by those who did (Group A) and did not (Group B) discontinue dialysis within 26 weeks of eculizumab treatment.

Results

Of 38 included patients, 21 (55.3%) and 17 (44.7%) were placed in Groups A and B, respectively. No patient re-started dialysis. Hypertension was less

SUBMITTER: Ito S 

PROVIDER: S-EPMC12712043 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature